|
1
|
Greish K: Enhanced permeability and
retention of macromolecular drugs in solid tumors: a royal gate for
targeted anticancer nanomedicines. J Drug Target. 15:457–464. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Greish K: Enhanced permeability and
retention (EPR) effect for anticancer nanomedicine drug targeting.
Methods Mol Biol. 624:25–37. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
LaRocque J, Bharali DJ and Mousa SA:
Cancer detection and treatment: the role of nanomedicines. Mol
Biotechnol. 42:358–366. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wang X, Wang Y, Chen ZG and Shin DM:
Advances of cancer therapy by nanotechnology. Cancer Res Treat.
41:1–11. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kreuter J: Nanoparticles - a historical
perspective. Int J Pharm. 331:1–10. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Byrne JD, Betancourt T and Brannon-Peppas
L: Active targeting schemes for nanoparticle systems in cancer
therapeutics. Adv Drug Deliv Rev. 60:1615–1626. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Maeda H and Matsumura Y: Tumoritropic and
lymphotropic principles of macromolecular drugs. Crit Rev Ther Drug
Carrier Syst. 6:193–210. 1989.PubMed/NCBI
|
|
8
|
Matsumura Y and Maeda H: A new concept for
macromolecular therapeutics in cancer chemotherapy: mechanism of
tumoritropic accumulation of proteins and the antitumor agent
smancs. Cancer Res. 46:6387–6392. 1986.
|
|
9
|
Maeda H, Matsumura Y and Oda T: Cancer
selective macromolecular therapeutics: tailoring of an antitumor
protein drug. Protein Tailoring for Food and Medical Uses. Feeny RE
and Whitaker JR: Marcel Dekker, Inc; New York: pp. 353–382.
1986
|
|
10
|
Maeda H, Takeshita J and Kanamaru R: A
lipophilic derivative of neocarzinostatin. A polymer conjugation of
an antitumor protein antibiotic. Int J Pept Protein Res. 14:81–87.
1979. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Maeda H: Vascular permeability in cancer
and infection as related to macromolecular drug delivery, with
emphasis on the EPR effect for tumor-selective drug targeting. Proc
Jpn Acad Ser B Phys Biol Sci. 88:53–71. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cho K, Wang X, Nie S, Chen ZG and Shin DM:
Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer
Res. 14:1310–1316. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Iyer AK, Khaled G, Fang J and Maeda H:
Exploiting the enhanced permeability and retention effect for tumor
targeting. Drug Discov Today. 11:812–818. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Skinner SA, Tutton PJ and O’Brien PE:
Microvascular architecture of experimental colon tumors in the rat.
Cancer Res. 50:2411–2417. 1990.PubMed/NCBI
|
|
15
|
Talekar M, Kendall J, Denny W and Garg S:
Targeting of nanoparticles in cancer: drug delivery and
diagnostics. Anticancer Drugs. 22:949–962. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kuruppu D, Christophi C, Maeda H and
O’Brien PE: Changes in the microvascular architecture of colorectal
liver metastases following the administration of SMANCS/lipiodol. J
Surg Res. 103:47–54. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Suzuki M, Hori K, Abe I, Saito S and Sato
H: A new approach to cancer chemotherapy: selective enhancement of
tumor blood flow with angiotensin II. J Natl Cancer Inst.
67:663–669. 1981.PubMed/NCBI
|
|
18
|
Li CJ, Miyamoto Y, Kojima Y and Maeda H:
Augmentation of tumour delivery of macromolecular drugs with
reduced bone marrow delivery by elevating blood pressure. Br J
Cancer. 67:975–980. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wu J, Akaike T and Maeda H: Modulation of
enhanced vascular permeability in tumors by a bradykinin
antagonist, a cyclooxygenase inhibitor, and a nitric oxide
scavenger. Cancer Res. 58:159–165. 1998.PubMed/NCBI
|
|
20
|
Maeda H: The enhanced permeability and
retention (EPR) effect in tumor vasculature: the key role of
tumor-selective macromolecular drug targeting. Adv Enzyme Regul.
41:189–207. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Seki T, Fang J and Maeda H: Tumor-targeted
macromolecular drug delivery based on the enhanced permeability and
retention effect in solid tumor. Pharmaceutical Perspectives of
Cancer Therapeutics. Lu Y and Mahato RI: Springer; New York: pp.
93–120. 2009, View Article : Google Scholar
|
|
22
|
Wu J, Akaike T, Hayashida K, Miyamoto Y,
Nakagawa T, Miyakawa K, Müller-Esterl W and Maeda H: Identification
of bradykinin receptors in clinical cancer specimens and murine
tumor tissues. Int J Cancer. 98:29–35. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bhoola K, Ramsaroop R, Plendl J, Cassim B,
Dlamini Z and Naicker S: Kallikrein and kinin receptor expression
in inflammation and cancer. Biol Chem. 382:77–89. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Matsumura Y, Kimura M, Yamamoto T and
Maeda H: Involvement of the kinin-generating cascade in enhanced
vascular permeability in tumor tissue. Jpn J Cancer Res.
79:1327–1334. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kou R, Greif D and Michel T:
Dephosphorylation of endothelial nitric-oxide synthase by vascular
endothelial growth factor. Implications for the vascular responses
to cyclosporin A. J Biol Chem. 277:29669–29673. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Papapetropoulos A, Garcia-Cardena G, Madri
JA and Sessa WC: Nitric oxide production contributes to the
angiogenic properties of vascular endothelial growth factor in
human endothelial cells. J Clin Invest. 100:3131–3139. 1997.
View Article : Google Scholar
|
|
27
|
Maeda H, Wu J, Okamoto T, et al:
Kallikrein-kinin in infection and cancer. Immunopharmacology.
43:115–128. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hori K, Saito S, Takahashi H, Sato H,
Maeda H and Sato Y: Tumor-selective blood flow decrease induced by
an angiotensin converting enzyme inhibitor, temocapril
hydrochloride. Jpn J Cancer Res. 91:261–269. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Noguchi A, Takahashi T, Yamaguchi T, et
al: Enhanced tumor localization of monoclonal antibody by treatment
with kininase II inhibitor and angiotensin II. Jpn J Cancer Res.
83:240–243. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Maeda H, Fang J, Inutsuka T and Kitamoto
Y: Vascular permeability enhancement in solid tumor: various
factors, mechanisms involved and its implications. Int
Immunopharmacol. 3:319–328. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Maeda H, Noguchi Y, Sato K and Akaike T:
Enhanced vascular permeability in solid tumor is mediated by nitric
oxide and inhibited by both new nitric oxide scavenger and nitric
oxide synthase inhibitor. Jpn J Cancer Res. 85:331–334. 1994.
View Article : Google Scholar
|
|
32
|
Okamoto T, Akaike T, Sawa T, Miyamoto Y,
van der Vliet A and Maeda H: Activation of matrix
metalloproteinases by peroxynitrite-induced protein
S-glutathiolation via disulfide S-oxide formation. J Biol Chem.
276:29596–29602. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Maeda H: Nitroglycerin enhances vascular
blood flow and drug delivery in hypoxic tumor tissues: analogy
between angina pectoris and solid tumors and enhancement of the EPR
effect. J Control Release. 142:296–298. 2010. View Article : Google Scholar
|
|
34
|
Seki T, Fang J and Maeda H: Enhanced
delivery of macromolecular antitumor drugs to tumors by
nitroglycerin application. Cancer Sci. 100:2426–2430. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yasuda H, Yamaya M, Nakayama K, et al:
Randomized phase II trial comparing nitroglycerin plus vinorelbine
and cisplatin with vinorelbine and cisplatin alone in previously
untreated stage IIIB/IV non-small-cell lung cancer. J Clin Oncol.
24:688–694. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yasuda H, Nakayama K, Watanabe M, et al:
Nitroglycerin treatment may enhance chemosensitivity to docetaxel
and carboplatin in patients with lung adenocarcinoma. Clin Cancer
Res. 12:6748–6757. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Siemens DR, Heaton JP, Adams MA, Kawakami
J and Graham CH: Phase II study of nitric oxide donor for men with
increasing prostate-specific antigen level after surgery or
radiotherapy for prostate cancer. Urology. 74:878–883. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Himelstein BP, Canete-Soler R, Bernhard
EJ, Dilks DW and Muschel RJ: Metalloproteinases in tumor
progression: the contribution of MMP-9. Invasion Metastasis.
14:246–258. 1994.PubMed/NCBI
|
|
39
|
Chambers AF and Matrisian LM: Changing
views of the role of matrix metalloproteinases in metastasis. J
Natl Cancer Inst. 89:1260–1270. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wu J, Akaike T, Hayashida K, Okamoto T,
Okuyama A and Maeda H: Enhanced vascular permeability in solid
tumor involving peroxynitrite and matrix metalloproteinases. Jpn J
Cancer Res. 92:439–451. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Tanaka S, Akaike T, Wu J, Fang J, Sawa T,
Ogawa M, et al: Modulation of tumor-selective vascular blood flow
and extravasation by the stable prostaglandin 12 analogue beraprost
sodium. J Drug Target. 11:45–52. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Moghimi SM, Hunter AC and Murray JC:
Long-circulating and target-specific nanoparticles: theory to
practice. Pharmacol Rev. 53:283–318. 2001.PubMed/NCBI
|
|
43
|
Huynh NT, Roger E, Lautram N, Benoit JP
and Passirani C: The rise and rise of stealth nanocarriers for
cancer therapy: passive versus active targeting. Nanomedicine
(Lond). 5:1415–1433. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Wang M and Thanou M: Targeting
nanoparticles to cancer. Pharmacol Res. 62:90–99. 2010. View Article : Google Scholar
|
|
45
|
Singh R and Lillard JW Jr:
Nanoparticle-based targeted drug delivery. Exp Mol Pathol.
86:215–223. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Torchilin VP: Passive and active drug
targeting: drug delivery to tumors as an example. Handb Exp
Pharmacol. 197:3–53. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Fang J, Nakamura H and Maeda H: The EPR
effect: unique features of tumor blood vessels for drug delivery,
factors involved, and limitations and augmentation of the effect.
Adv Drug Deliv Rev. 63:136–151. 2011. View Article : Google Scholar : PubMed/NCBI
|
